Levosimendan in Cardiogenic Shock: A Review of Mechanisms, Clinical Evidence, and Therapeutic Use.

Levosimendan is a calcium-sensitizing inodilator that has attracted renewed attention for a potential role in the management of cardiogenic shock (CS). The pharmacological profile of levosimendan differs markedly from that of adrenergic inotropes: levosimendan augments contractile force without increasing intracellular calcium or myocardial oxygen demand and, through activation of ATP-sensitive (KATP) potassium channels, produces systemic and coronary vasodilation. Experimental and clinical data also suggest additional protective effects, including modulation of inflammatory pathways, anti-apoptotic activity, and improved mitochondrial function. Although these mechanisms translate into consistent hemodynamic improvement across several studies, large, randomized trials have not demonstrated a consistent survival advantage, likely due to differences in patient selection, treatment timing, and concomitant therapies. Nevertheless, certain clinical groups, such as patients who fail to respond to catecholamines, individuals on chronic β-blockers, and selected perioperative or mechanically supported patients, appear more likely to benefit. Therefore, current guidance favors an individualized rather than universal approach to levosimendan use. Several ongoing investigations, including trials in extracorporeal membrane oxygenation (ECMO)-supported patients and those with septic cardiomyopathy, may help clarify the optimal indications and timing for levosimendan use. This review integrates mechanistic, clinical, and safety data to identify patient profiles most suited to levosimendan therapy and to outline areas where further study is needed.